Inamrinone
Amrinone (inamrinone) is a small molecule pharmaceutical. Inamrinone was first approved as Inocor on 1984-07-31. It is used to treat cardiogenic shock, dilated cardiomyopathy, heart failure, and low cardiac output in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A and cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Amrinone (discontinued: Amrinone, Inocor)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 3 | 4 | — | 1 | 2 | 8 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 4 | 2 | 1 | 1 | 8 |
| Low cardiac output | D002303 | — | — | 1 | 2 | 2 | 1 | 2 | 7 |
| Cardiogenic shock | D012770 | — | R57.0 | 1 | — | — | 2 | — | 3 |
| Cardio-renal syndrome | D059347 | — | — | — | 1 | — | 1 | — | 2 |
| Septic shock | D012772 | — | A48.3 | — | 1 | — | 1 | — | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | — | — | 1 | — | 1 |
| Hemodynamics | D006439 | — | — | — | — | — | 1 | — | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | — | — | 2 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | 1 | — | — | 2 |
| Spasm | D013035 | — | M62.83 | — | 1 | 1 | — | — | 2 |
| Cardiac surgical procedures | D006348 | — | — | — | — | 1 | — | — | 1 |
| Mitral valve insufficiency | D008944 | — | — | — | — | 1 | — | — | 1 |
| Aneurysm | D000783 | — | I72.9 | — | — | 1 | — | — | 1 |
| Vasodilation | D014664 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | — | Q24.9 | 1 | 4 | — | — | 1 | 5 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 2 | — | — | 1 | 3 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 3 | — | — | — | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | 2 | 3 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | 1 | — | — | 2 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | — | — | 1 | 2 |
| Right ventricular dysfunction | D018497 | — | — | 1 | 1 | — | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
| Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 2 | 2 |
| Cardiopulmonary bypass | D002315 | — | — | — | — | — | — | 2 | 2 |
| Sprains and strains | D013180 | — | — | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
Show 29 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Inamrinone |
| INN | amrinone |
| Description | Amrinone is a 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. It has a role as an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor. |
| Classification | Small molecule |
| Drug class | cardiotonics (amrinone type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1cc(-c2ccncc2)c[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 60719-84-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL12856 |
| ChEBI ID | — |
| PubChem CID | 3698 |
| DrugBank | DB01427 |
| UNII ID | JUT23379TN (ChemIDplus, GSRS) |
Target
Agency Approved
PDE3A
PDE3A
PDE3B
PDE3B
Organism
Homo sapiens
Gene name
PDE3A
Gene synonyms
NCBI Gene ID
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Protein synonyms
cAMP phosphodiesterase, myocardial cGMP-inhibited, cGI-PDE, CGI-PDE A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited cAMP phosphodiesterase, Cyclic GMP-inhibited phosphodiesterase A, phosphodiesterase 3A, cGMP-inhibited
Uniprot ID
Mouse ortholog
Pde3a (54611)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (Q9Z0X4)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,122 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,114 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use